Biopharmaceutical company AbbVie (ABBV.US) announced on Friday that it has applied to the US Food and Drug Administration for accelerated approval of its antibody-drug conjugate for certain lung cancer patients.

The company noted that the application covers telisotuzumab vedotin or teliso-V, to be used in the treatment of adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor wild-type, non-squamous non-small cell lung cancer and c-Met protein overexpression.